Washing Illness Away: A Systematic Review of the Impact of Nasal Irrigation and Spray on COVID-19.
COVID‐19
INCS
PVP‐I
nasal saline irrigation
viral load
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
revised:
15
08
2024
received:
11
06
2024
accepted:
28
08
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
13
9
2024
Statut:
aheadofprint
Résumé
Nasal irrigation is a common treatment for sinonasal disorders; however, it is unknown if it can reduce SARS-CoV-2 nasopharyngeal viral load (NVL). This systematic review investigated the efficacy of nasal irrigation with saline, povidone iodine (PVP-I), and intranasal corticosteroids (INCS) at reducing SARS-CoV-2 NVL and transmissibility. Databases including Embase, MEDLINE, Web of Science, and ClinicalTrials.gov. A systematic review was completed with pre-defined search criteria using keywords related to nasal irrigation and COVID-19 from 1946 through January 2024. This review followed PRISMA reporting guidelines and was registered on PROSPERO. Only in-vivo studies testing nasal irrigation with either saline, PVP-I, or INCS for reducing NVL were included. Nine out of ten studies on saline-based solutions reported positive effects in reducing NVL, with benefits noted in earlier time to negative nasopharyngeal PCR and a greater decline in NVL during early study time points, compared with controls. Isotonic and hypertonic saline mediums were found to be effective with three studies demonstrating enhanced efficacy with additives. Four out of seven studies on PVP-I showed a positive effect on reducing NVL, but results were heterogenous. Four studies demonstrated reduction of transmission with saline or PVP-I. No studies were found on INCS. Saline nasal irrigation showed the best efficacy in reducing SARS-CoV-2 NVL. Additives to saline may have a clinical benefit, but further studies are needed to elucidate their isolated impacts on NVL. Data on PVP-I is inconclusive and further studies are warranted to determine the ideal concentration for irrigation. Laryngoscope, 2024.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.
Références
Coronavirus (COVID‐19) | IPAC Canada. Accessed June 9, 2024. https://ipac-canada.org/coronavirus-resources
Triggle CR, Bansal D, Ding H, et al. A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS‐CoV‐2 and COVID‐19 as a basis for controlling the pandemic. Front Immunol. 2021;12:12. https://doi.org/10.3389/fimmu.2021.631139.
Sungnak W, Huang N, Bécavin C, et al. SARS‐CoV‐2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681‐687. https://doi.org/10.1038/s41591-020-0868-6.
Hou YJ, Okuda K, Edwards CE, et al. SARS‐CoV‐2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182(2):429‐446. https://doi.org/10.1016/j.cell.2020.05.042.
Parasher A. COVID‐19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312‐320. https://doi.org/10.1136/postgradmedj-2020-138577.
Marc A, Kerioui M, Blanquart F, et al. Quantifying the relationship between SARS‐CoV‐2 viral load and infectiousness. eLife. 2021;10:e69302. https://doi.org/10.7554/eLife.69302.
Jajou R, Mutsaers‐ van Oudheusden A, Verweij JJ, Rietveld A, Murk JL. SARS‐CoV‐2 transmitters have more than three times higher viral loads than non‐transmitters – practical use of viral load for disease control. J Clin Virol. 2022;150:105131. https://doi.org/10.1016/j.jcv.2022.105131.
Hastie E, Amogan H, Looney D, Mehta SR. Association between SARS‐CoV‐2 viral load and patient symptoms and clinical outcomes using droplet digital PCR. Viruses. 2023;15(2):446. https://doi.org/10.3390/v15020446.
Bastier PL, Lechot A, Bordenave L, Durand M, de Gabory L. Nasal irrigation: from empiricism to evidence‐based medicine. A review. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132(5):281‐285. https://doi.org/10.1016/j.anorl.2015.08.001.
Abdullah B, Periasamy C, Ismail R. Nasal irrigation as treatment in Sinonasal symptoms relief: a review of its efficacy and clinical applications. Indian J Otolaryngol Head Neck Surg. 2019;71(Suppl 3):1718‐1726. https://doi.org/10.1007/s12070-017-1070-0.
Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A. A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Sci Rep. 2019;9:1015. https://doi.org/10.1038/s41598-018-37703-3.
Panta P, Chatti K, Andhavarapu A. Do saline water gargling and nasal irrigation confer protection against COVID‐19? Explore (NY). 2021;17(2):127‐129. https://doi.org/10.1016/j.explore.2020.09.010.
Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID‐19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open‐label, adaptive platform trial. Lancet. 2021;398(10303):843‐855. https://doi.org/10.1016/S0140-6736(21)01744-X.
Rocha SM, Fagre AC, Latham AS, et al. A novel glucocorticoid and androgen receptor modulator reduces viral entry and innate immune inflammatory responses in the Syrian hamster model of SARS‐CoV‐2 infection. Front Immunol. 2022;13:811430. https://doi.org/10.3389/fimmu.2022.811430.
Frank S, Brown SM, Capriotti JA, Westover JB, Pelletier JS, Tessema B. In vitro efficacy of a povidone‐iodine nasal antiseptic for rapid inactivation of SARS‐CoV‐2. JAMA Otolaryngol Head Neck Surg. 2020;146(11):1‐5. https://doi.org/10.1001/jamaoto.2020.3053.
Anderson DE, Sivalingam V, Kang AEZ, et al. Povidone‐iodine demonstrates rapid in vitro Virucidal activity against SARS‐CoV‐2, the virus causing COVID‐19 disease. Infect Dis Ther. 2020;9(3):669‐675. https://doi.org/10.1007/s40121-020-00316-3.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.
Pantazopoulos I, Chalkias A, Mavrovounis G, et al. Nasopharyngeal wash with normal saline decreases SARS‐CoV‐2 viral load: a randomized pilot controlled trial. Can Respir J. 2022;2022:8794127. https://doi.org/10.1155/2022/8794127.
Spinato G, Fabbris C, Costantini G, et al. The effect of isotonic saline nasal lavages in improving symptoms in SARS‐CoV‐2 infection: a case‐control study. Front Neurol. 2021;12:794471. https://doi.org/10.3389/fneur.2021.794471.
Liu L, Wang C, Xie S, Su L, Wang C. Effect of nasal irrigation in children with omicron variant of COVID‐19 infection. Ear Nose Throat J. 2023;103:59S. https://doi.org/10.1177/01455613231172337.
Liu L, Xie S, Li C, Su L, Zhu C. Effect of nasal irrigation in adults infected with omicron variant of COVID‐19: a quasi‐experimental study. Front Public Health. 2022;10:1046112. https://doi.org/10.3389/fpubh.2022.1046112.
Wang T, Zhang Y, Zhang R, et al. Efficacy of nasal irrigation and oral rinse with sodium bicarbonate solution on virus clearance for COVID‐19 patients. Front Public Health. 2023;11:1145669. https://doi.org/10.3389/fpubh.2023.1145669.
Yilmaz YZ, Yilmaz BB, Ozdemir YE, et al. Effects of hypertonic alkaline nasal irrigation on COVID‐19. Laryngoscope Investig Otolaryngol. 2021;6(6):1240‐1247. https://doi.org/10.1002/lio2.686.
Pantazopoulos I, Chalkias A, Miziou A, et al. A hypertonic seawater nasal irrigation solution containing algal and herbal natural ingredients reduces viral load and SARS‐CoV‐2 detection time in the nasal cavity. J Pers Med. 2023;13(7):1093. https://doi.org/10.3390/jpm13071093.
Varricchio ALM, Brunese FP, Varricchio A, Ciprandi G. Viral shedding in symptomatic patients with mild COVID‐19: an experience with nebulized nasal treatment. J Biol Regul Homeost Agents. 2021;35(3):1155‐1157. https://doi.org/10.23812/21-137-L.
Cegolon L, Mastrangelo G, Emanuelli E, Camerotto R, Spinato G, Frezza D. Early negativization of SARS‐CoV‐2 infection by nasal spray of seawater plus additives: the RENAISSANCE open‐label controlled clinical trial. Pharmaceutics. 2022;14(11):2502. https://doi.org/10.3390/pharmaceutics14112502.
Esther CR Jr, Kimura KS, Mikami Y, et al. Pharmacokinetic‐based failure of a detergent virucidal for severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) nasal infections: a preclinical study and randomized controlled trial. Int Forum Allergy Rhinol. 2022;12(9):1137‐1147. https://doi.org/10.1002/alr.22975.
Sharma P, Singh A, Singh NP, Takhelchangbam N, Kumar R, Yadav R. Effect of 0.5% povidone‐iodine on the nasopharyngeal and oropharyngeal viral loads in patients with COVID‐19: a double‐blind placebo‐controlled randomized clinical trial. J Family Med Prim Care. 2022;11(10):6320‐6326. https://doi.org/10.4103/jfmpc.jfmpc_446_22.
Kamal Arefin M, Banu SS, Nasir Uddin AKM, et al. Virucidal effect of povidone iodine on SARS‐CoV‐2 in nasopharynx: an open‐label randomized clinical trial. Indian J Otolaryngol Head Neck Surg. 2022;74(2):3283‐3292. https://doi.org/10.1007/s12070-022-03106-0.
Elsersy HE, Zahran MAH, Elbakry AE, et al. Combined nasal, oropharyngeal povidone iodine plus Glycyrrhizic acid sprays, accelerate clinical and laboratory recovery and reduces household transmission of SARS‐CoV‐2: a randomized placebo‐controlled clinical trial. Front Med. 2022;9:863917. https://doi.org/10.3389/fmed.2022.863917.
Batioglu‐Karaaltin A, Yigit O, Cakan D, et al. Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID‐19. Clin Otolaryngol. 2023;48(4):623‐629. https://doi.org/10.1111/coa.14056.
Guenezan J, Garcia M, Strasters D, et al. Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID‐19. JAMA Otolaryngol Head Neck Surg. 2021;147(4):400‐401. https://doi.org/10.1001/jamaoto.2020.5490.
Sirijatuphat R, Leelarasamee A, Puangpet T, Thitithanyanont A. A pilot study of 0.4% povidone‐iodine nasal spray to eradicate SARS‐CoV‐2 in the nasopharynx. Infect Drug Resist. 2022;15:7529‐7536. https://doi.org/10.2147/IDR.S391630.
Zarabanda D, Vukkadala N, Phillips KM, et al. The effect of povidone‐iodine nasal spray on nasopharyngeal SARS‐CoV‐2 viral load: a randomized control trial. Laryngoscope. 2022;132(11):2089‐2095. https://doi.org/10.1002/lary.29935.
Gutiérrez‐García R, De La Cerda‐Ángeles JC, Cabrera‐Licona A, Delgado‐Enciso I, Mervitch‐Sigal N, Paz‐Michel BA. Nasopharyngeal and oropharyngeal rinses with neutral electrolyzed water prevents COVID‐19 in front‐line health professionals: a randomized, open‐label, controlled trial in a general hospital in Mexico City. Biomed Rep. 2022;16(2):11. https://doi.org/10.3892/br.2021.1494.
Baxter AL, Schwartz KR, Johnson RW, et al. Rapid initiation of nasal saline irrigation to reduce severity in high‐risk COVID+ outpatients. Ear Nose Throat J. 2024;103(1_suppl):30S‐39S. https://doi.org/10.1177/01455613221123737.
Lei H, Xu X, Xiao S, Wu X, Shu Y. Household transmission of COVID‐19‐a systematic review and meta‐analysis. J Infect. 2020;81(6):979‐997. https://doi.org/10.1016/j.jinf.2020.08.033.
Balmforth D, Swales JA, Silpa L, et al. Evaluating the efficacy and safety of a novel prophylactic nasal spray in preventing SARS‐CoV‐2 infection: a multi‐centre, double‐blind, placebo‐controlled, randomized trial. J Clin Virol. 2022;155:105248. https://doi.org/10.1016/j.jcv.2022.105248.
Huijghebaert S, Hoste L, Vanham G. Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID‐19. Eur J Clin Pharmacol. 2021;77(9):1275‐1293. https://doi.org/10.1007/s00228-021-03102-3.
Rabago D, Zgierska A. Saline nasal irrigation for upper respiratory conditions. Am Fam Physician. 2009;80(10):1117‐1119.
Liu L, Pan M, Li Y, Tan G, Yang Y. Efficacy of nasal irrigation with hypertonic saline on chronic rhinosinusitis: systematic review and meta‐analysis. Braz J Otorhinolaryngol. 2020;86(5):639‐646. https://doi.org/10.1016/j.bjorl.2020.03.008.
Kimura KS, Freeman MH, Wessinger BC, et al. Interim analysis of an open‐label randomized controlled trial evaluating nasal irrigations in non‐hospitalized patients with coronavirus disease 2019. Int Forum Allergy Rhinol. 2020;10(12):1325‐1328. https://doi.org/10.1002/alr.22703.
Pujadas E, Chaudhry F, McBride R, et al. SARS‐CoV‐2 viral load predicts COVID‐19 mortality. Lancet Respir. 2020;8(9):e70.
Achilles N, Mösges R. Nasal saline irrigations for the symptoms of acute and chronic Rhinosinusitis. Curr Allergy Asthma Rep. 2013;13(2):229‐235. https://doi.org/10.1007/s11882-013-0339-y.
Cnockaert P, Vecellio L, Dubus JC, Jamar F, Reychler G. A large‐volume low‐pressure nasal irrigation delivers drug into the nasal cavity? An in vivo study. Drug Deliv Transl Res. 2024;14(5):1232‐1238. https://doi.org/10.1007/s13346-023-01455-z.
de Gabory L, Kérimian M, Baux Y, Boisson N, Bordenave L. Computational fluid dynamics simulation to compare large volume irrigation and continuous spraying during nasal irrigation. Int Forum Allergy Rhinol. 2020;10(1):41‐48. https://doi.org/10.1002/alr.22458.
Salli K, Lehtinen MJ, Tiihonen K, Ouwehand AC. Xylitol's health benefits beyond dental health: a comprehensive review. Nutrients. 2019;11(8):1813. https://doi.org/10.3390/nu11081813.
Cannon ML, Westover JB, Bleher R, Sanchez‐Gonzalez MA, Ferrer GA. In vitro analysis of the anti‐viral potential of nasal spray constituents against SARS‐CoV‐2. bioRxiv. 2020. https://doi.org/10.1101/2020.12.02.408575.
Soler E, de Mendoza A, Cuello VI, et al. Intranasal xylitol for the treatment of COVID‐19 in the outpatient setting: a pilot study. Cureus. 2022;14(7):e27182. https://doi.org/10.7759/cureus.27182.
Go CC, Pandav K, Sanchez‐Gonzalez MA, Ferrer G. Potential role of xylitol plus grapefruit seed extract nasal spray solution in COVID‐19: case series. Cureus. 2020;12(11):e11315. https://doi.org/10.7759/cureus.11315.
Lipworth BJ, Chan R, Carr T. Corticosteroid protection against COVID‐19: begin with the nose. J Allergy Clin Immunol Pract. 2021;9(11):3941‐3943. https://doi.org/10.1016/j.jaip.2021.08.025.
Peters MC, Sajuthi S, Deford P, et al. COVID‐19–related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83‐90. https://doi.org/10.1164/rccm.202003-0821OC.
Strauss R, Jawhari N, Attaway AH, et al. Intranasal corticosteroids are associated with better outcomes in coronavirus disease 2019. J Allergy Clin Immunol Pract. 2021;9(11):3934‐3940. https://doi.org/10.1016/j.jaip.2021.08.007.